Muller Matthieu, Chérel Michel, Dupré Pierre-François, Gouard Sébastien, Collet Michel, Classe Jean-Marc
Unit of Gynecological and Mammary Oncologic Surgery, Centre Hospitalier Universitaire Augustin Morvan, Brest, France.
Eur Surg Res. 2011;46(3):139-47. doi: 10.1159/000324395. Epub 2011 Mar 4.
Hyperthermic intraperitoneal chemotherapy is continuously under evaluation in ovarian cancer. The purpose of the present study was to evaluate the effect of chemotherapy, drug concentration and temperature.
A human ovarian carcinoma cell line was used. The effect of hyperthermia combined with chemotherapy was analyzed.
When hyperthermia was combined with chemotherapy, the 50% lethal dose (LD(50)) decreased with the duration of exposure. The effect of temperature was similar between 39 and 43 °C for a 30-min exposure. For a 60- to 90-min exposure, the LD(50) was equivalent between 38 and 43 °C. Beyond 40 °C, an increase in platinum salt concentration was necessary to obtain similar results according to the duration of exposure.
The cytotoxic effect of the combination seemed to be potentiated and limited at 40 °C.
热腹腔内化疗在卵巢癌治疗中一直处于评估阶段。本研究的目的是评估化疗、药物浓度和温度的影响。
使用人卵巢癌细胞系。分析热疗联合化疗的效果。
热疗联合化疗时,50%致死剂量(LD(50))随暴露时间延长而降低。暴露30分钟时,39至43°C之间温度的影响相似。暴露60至90分钟时,38至43°C之间LD(50)相当。超过40°C时,根据暴露时间,需要增加铂盐浓度才能获得相似结果。
联合治疗的细胞毒性作用似乎在40°C时增强且受到限制。